語系:
繁體中文
English
說明(常見問題)
回圖書館首頁
手機版館藏查詢
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Apolipoprotein A-I inhibits atherosc...
~
Moore, Ryan E.
FindBook
Google Book
Amazon
博客來
Apolipoprotein A-I inhibits atherosclerosis in vivo by promoting macrophage reverse cholesterol transport and HDL anti-inflammatory and anti-oxidant functions.
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Apolipoprotein A-I inhibits atherosclerosis in vivo by promoting macrophage reverse cholesterol transport and HDL anti-inflammatory and anti-oxidant functions./
作者:
Moore, Ryan E.
面頁冊數:
237 p.
附註:
Adviser: Daniel J. Rader.
Contained By:
Dissertation Abstracts International67-12B.
標題:
Biology, Molecular. -
電子資源:
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3246206
Apolipoprotein A-I inhibits atherosclerosis in vivo by promoting macrophage reverse cholesterol transport and HDL anti-inflammatory and anti-oxidant functions.
Moore, Ryan E.
Apolipoprotein A-I inhibits atherosclerosis in vivo by promoting macrophage reverse cholesterol transport and HDL anti-inflammatory and anti-oxidant functions.
- 237 p.
Adviser: Daniel J. Rader.
Thesis (Ph.D.)--University of Pennsylvania, 2006.
Although it is well established that HDL is anti-atherogenic, the mechanisms by which it inhibits atherosclerosis in vivo have not been definitively proven. The goals of this thesis are fourfold: First, to test the hypothesis that apolipoprotein A-I (apoA-I), the primary protein component of HDL, is directly anti-atherogenic. Second, to determine the in vivo relevance of mechanisms by which apoA-I is presumed to inhibit the development of atherosclerosis. In vitro studies have suggested that apoA-I may promote reverse cholesterol transport, inhibit oxidation, and inhibit inflammation, however the role of apoA-I in these processes in vivo has not been clearly established. Third, to gain a better understanding of HDL anti-atherogenic function, with a particular emphasis on understanding the relationship between apoA-I and HDL function. Lastly, to identify novel mechanisms by which apoA-I may function to inhibit the development of atherosclerosis. In order to pursue these goals we established atherosclerosis-susceptible mouse models of apoA-I deficiency as well as models of transgenic expression and overexpression of human apoA-I. Using these models we determined how apoA-I genotype effected the development of atherosclerosis. In addition we determined how apoA-I genotype influenced the reverse cholesterol transport pathway and HDL anti-oxidant and anti-inflammatory function. To identify novel mechanisms by which apoA-I and HDL function to inhibit the development of atherosclerosis we used both the animal models as well as in vitro studies. Our results indicate that apoA-I is directly anti-atherogenic in vivo, independent of the level of HDL cholesterol. Furthermore, apoA-I is required for efficient reverse cholesterol transport as well as for HDL anti-oxidant and anti-inflammatory functions in vivo. We offer a new connection between the lipid-transporting and anti-oxidant and anti-inflammatory functions of apoA-I by demonstrating that apoA-I is an efficient acceptor of ABCA1-mediated oxidized phospholipid efflux from macrophage cells. In conclusion, apoA-I is directly anti-atherogenic by promotion of macrophage reverse cholesterol transport and HDL antioxidant and anti-inflammatory functions. Strategies to augment the level or functional capacity of apoA-I may represent effective options in the prevention and treatment of cardiovascular disease.Subjects--Topical Terms:
1017719
Biology, Molecular.
Apolipoprotein A-I inhibits atherosclerosis in vivo by promoting macrophage reverse cholesterol transport and HDL anti-inflammatory and anti-oxidant functions.
LDR
:03324nam 2200265 a 45
001
970685
005
20110921
008
110921s2006 eng d
035
$a
(UMI)AAI3246206
035
$a
AAI3246206
040
$a
UMI
$c
UMI
100
1
$a
Moore, Ryan E.
$3
1294721
245
1 0
$a
Apolipoprotein A-I inhibits atherosclerosis in vivo by promoting macrophage reverse cholesterol transport and HDL anti-inflammatory and anti-oxidant functions.
300
$a
237 p.
500
$a
Adviser: Daniel J. Rader.
500
$a
Source: Dissertation Abstracts International, Volume: 67-12, Section: B, page: 6897.
502
$a
Thesis (Ph.D.)--University of Pennsylvania, 2006.
520
$a
Although it is well established that HDL is anti-atherogenic, the mechanisms by which it inhibits atherosclerosis in vivo have not been definitively proven. The goals of this thesis are fourfold: First, to test the hypothesis that apolipoprotein A-I (apoA-I), the primary protein component of HDL, is directly anti-atherogenic. Second, to determine the in vivo relevance of mechanisms by which apoA-I is presumed to inhibit the development of atherosclerosis. In vitro studies have suggested that apoA-I may promote reverse cholesterol transport, inhibit oxidation, and inhibit inflammation, however the role of apoA-I in these processes in vivo has not been clearly established. Third, to gain a better understanding of HDL anti-atherogenic function, with a particular emphasis on understanding the relationship between apoA-I and HDL function. Lastly, to identify novel mechanisms by which apoA-I may function to inhibit the development of atherosclerosis. In order to pursue these goals we established atherosclerosis-susceptible mouse models of apoA-I deficiency as well as models of transgenic expression and overexpression of human apoA-I. Using these models we determined how apoA-I genotype effected the development of atherosclerosis. In addition we determined how apoA-I genotype influenced the reverse cholesterol transport pathway and HDL anti-oxidant and anti-inflammatory function. To identify novel mechanisms by which apoA-I and HDL function to inhibit the development of atherosclerosis we used both the animal models as well as in vitro studies. Our results indicate that apoA-I is directly anti-atherogenic in vivo, independent of the level of HDL cholesterol. Furthermore, apoA-I is required for efficient reverse cholesterol transport as well as for HDL anti-oxidant and anti-inflammatory functions in vivo. We offer a new connection between the lipid-transporting and anti-oxidant and anti-inflammatory functions of apoA-I by demonstrating that apoA-I is an efficient acceptor of ABCA1-mediated oxidized phospholipid efflux from macrophage cells. In conclusion, apoA-I is directly anti-atherogenic by promotion of macrophage reverse cholesterol transport and HDL antioxidant and anti-inflammatory functions. Strategies to augment the level or functional capacity of apoA-I may represent effective options in the prevention and treatment of cardiovascular disease.
590
$a
School code: 0175.
650
4
$a
Biology, Molecular.
$3
1017719
650
4
$a
Biology, Physiology.
$3
1017816
690
$a
0307
690
$a
0719
710
2 0
$a
University of Pennsylvania.
$3
1017401
773
0
$t
Dissertation Abstracts International
$g
67-12B.
790
$a
0175
790
1 0
$a
Rader, Daniel J.,
$e
advisor
791
$a
Ph.D.
792
$a
2006
856
4 0
$u
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3246206
筆 0 讀者評論
館藏地:
全部
電子資源
出版年:
卷號:
館藏
1 筆 • 頁數 1 •
1
條碼號
典藏地名稱
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
W9129173
電子資源
11.線上閱覽_V
電子書
EB W9129173
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
評論
新增評論
分享你的心得
Export
取書館
處理中
...
變更密碼
登入